The IXC patent relates to pressure disease on the brain. This also includes TBI, CVA, hydrocephalus, meningitis, among others. This is actually contained in the company’s earlier releases.
Unfortunately though I disagree. IMO they will do nothing with another indication until they prove that it reduces ICP and hopefully PMD improvement then use that as the upsell for the asset price when talking to big pharma. I don’t think they will do anything with another indication until efficacy is proven to reduce ICP.
The IXC patent relates to pressure disease on the brain. This...
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $5.411M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 158 | 7.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.0¢ | 5000 | 1 |
View Market Depth
| Last trade - 16.12pm 29/07/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable